---
title: "Interesting video"
image: "https:\/\/i.ytimg.com\/vi\/ufy2AweXRkc\/hqdefault.jpg"
vid_id: "ufy2AweXRkc"
categories: "Education"
tags: ["physiology","nursing","NCLEX"]
date: "2021-11-10T12:34:39+03:00"
vid_date: "2021-11-09T13:58:35Z"
duration: "PT22M25S"
viewcount: "331550"
likeCount: "18392"
dislikeCount: "425"
channel: "Dr. John Campbell"
---
{% raw %}New Pfizer antiviral and ivermectin, a pharmacodynamic analysis<br /><br />New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄<br /><br />PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,<br /><br /><a rel="nofollow" target="blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate">https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</a><br /><br />So, what is a protease?<br /><br />So what is a protease inhibitor?<br /><br />And, what is 3CL?<br /><br />Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)<br /><br />Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020)<br /><br /><a rel="nofollow" target="blank" href="https://pubs.acs.org/doi/abs/10.1021/acsptsci.0c00108#">https://pubs.acs.org/doi/abs/10.1021/acsptsci.0c00108#</a><br /><br />The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds<br /><br />Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection<br /><br /><a rel="nofollow" target="blank" href="https://pubs.rsc.org/en/content/articlehtml/2021/cp/d1cp02967c">https://pubs.rsc.org/en/content/articlehtml/2021/cp/d1cp02967c</a><br /><br />the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket:<br /><br />Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents<br /><br /><a rel="nofollow" target="blank" href="https://www.nature.com/articles/s42003-020-01577-x">https://www.nature.com/articles/s42003-020-01577-x</a><br /><br />as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration. <br /><br />Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly.<br /><br />Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study<br /><br /><a rel="nofollow" target="blank" href="https://pubs.rsc.org/en/content/articlehtml/2020/ra/d0ra06379g">https://pubs.rsc.org/en/content/articlehtml/2020/ra/d0ra06379g</a><br /><br />From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1<br /><br /><a rel="nofollow" target="blank" href="https://bnf.nice.org.uk/medicinal-forms/remdesivir.html">https://bnf.nice.org.uk/medicinal-forms/remdesivir.html</a><br /><br />Ritonavir, C37H48N6O5S2<br /><br />Ivermectin, C48H74O14<br /><br />Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach<br /><br /><a rel="nofollow" target="blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/</a><br /> <br />We have documented an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6.<br /><br /> PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,<br /><br /><a rel="nofollow" target="blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate">https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</a><br /><br />Risk of virus developing resistance to PF-07321332<br /><br />Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2<br /><br /><a rel="nofollow" target="blank" href="https://www.frontiersin.org/articles/10.3389/fmicb.2020.592908/full">https://www.frontiersin.org/articles/10.3389/fmicb.2020.592908/full</a><br /><br />With SARS-CoV-2 S Spike protein<br /><br />Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2. <br /><br />In agreement to our findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor <br /><br />Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein)<br /><br />The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions <br /><br />Binding Interactions of Selected Drugs With Human ACE-2 Protein<br /><br />that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions <br /><br />With SARS-CoV-2 S Glycoprotein<br /><br />Ivermectin showed the highest binding affinity to the predicted active site of the protein<br /><br />With SARS-CoV-2 Nsp14 Protein<br /><br />ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions<br /><br />Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro<br /><br />Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions <br /><br />A brief message to world leaders<br /><br />Come on ya all{% endraw %}
